{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107743","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.587287+00:00","generated_at":"2026-05-16T23:38:32.181429+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rezolute reports Q1 FY2026 net loss $18.2M; Phase 3 sunRIZE topline due Dec 2025","bullets":["Cash & marketable securities $152.2M as of Sep 30, 2025, down from $167.9M on Jun 30.","Net loss $18.2M for Q1 FY2026 vs $15.4M a year ago; R&D $13.1M, G&A $6.7M.","Phase 3 sunRIZE (congenital HI) topline results expected December 2025; registrational alignment with FDA.","Streamlined single-arm Phase 3 upLIFT (tumor HI) enrollment underway; topline data H2 2026.","Virtual investor event Nov 10, 2025 featuring KOLs on commercial opportunity for ersodetug."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107743","json":"https://secwatch.observer/filing/0001104659-25-107743.json","markdown":"https://secwatch.observer/filing/0001104659-25-107743.md","text":"https://secwatch.observer/filing/0001104659-25-107743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/0001104659-25-107743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/tm2529989d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:38:32.181429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}